Donn G. Wishka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Donn G. Wishka has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Beverly A. Teicher
National Cancer Institute 2 Division of Cancer Treatment and Diagnosis National Institutes of Health, Bethesda, Maryland
7 shared publications - David Evans
Sirnaomics, Inc. , Suite 200, 20511 Seneca Meadows Parkway, Germantown, MD 20876
7 shared publications - Dmitriy Sonkin
National Cancer Institute, Division of Cancer Treatment and Diagnosis, Rockville, MD 20850, USA
7 shared publications - Eric C. Polley
Department of Public Health Sciences, University of Chicago, Chicago, IL
7 shared publications - James H. Doroshow
Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, USA
7 shared publications - Jerry Collins
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland
7 shared publications
Latest Publications
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessAnalytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessAnalytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- 7 August 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 93, 129433
Positive allosteric modulators of the α7 nicotinic acetylcholine receptor: SAR investigation around PNU-120596
- 7 August 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 93, 129433
Positive allosteric modulators of the α7 nicotinic acetylcholine receptor: SAR investigation around PNU-120596
- Open Access
- 7 August 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (11) , 1270-1279
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in the search for novel chemotherapeutics. The publicly available cell line characterization and compound screening data from the NCI-60 assay have significantly contributed to the understanding of cellular mechanisms targeted by new oncology agents. Signature sensitivity/resistance patterns generated for a given chemotherapeutic agent against the NCI-60 panel have long served as fingerprint presentations that encompass target information and the mechanism of action associated with the tested agent. We report the establishment of a new public NCI-60 resource based on the cell line screening of a large and growing set of 175 FDA-approved oncology drugs (AOD) plus >825 clinical and investigational oncology agents (IOA), representing a diverse set (>250) of therapeutic targets and mechanisms. This data resource is available to the public (https://ioa.cancer.gov) and includes the raw data from the screening of the IOA and AOD collection along with an extensive set of visualization and analysis tools to allow for comparative study of individual test compounds and multiple compound sets.
- 7 August 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (11) , 1270-1279
Open AccessTargeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in the search for novel chemotherapeutics. The publicly available cell line characterization and compound screening data from the NCI-60 assay have significantly contributed to the understanding of cellular mechanisms targeted by new oncology agents. Signature sensitivity/resistance patterns generated for a given chemotherapeutic agent against the NCI-60 panel have long served as fingerprint presentations that encompass target information and the mechanism of action associated with the tested agent. We report the establishment of a new public NCI-60 resource based on the cell line screening of a large and growing set of 175 FDA-approved oncology drugs (AOD) plus >825 clinical and investigational oncology agents (IOA), representing a diverse set (>250) of therapeutic targets and mechanisms. This data resource is available to the public (https://ioa.cancer.gov) and includes the raw data from the screening of the IOA and AOD collection along with an extensive set of visualization and analysis tools to allow for comparative study of individual test compounds and multiple compound sets.
- 10 June 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (14) , 4425-4436
Discovery ofN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship
N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the α7 neuronal nicotinic acetylcholine receptor (α7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective α7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.
- 10 June 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (14) , 4425-4436
Discovery ofN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship
N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the α7 neuronal nicotinic acetylcholine receptor (α7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective α7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.